glp-1 sleep apnea Will Drugs Disrupt the Market? GLP-1/Zepbound: Changing the Landscape of

Patient-level weight change data were unavailable, so the analysis cannot explain whether the observed differences were driven by weight loss, metabolic control, cardiovascular effects, direct tumor biology, or differences in patient selection

The study was approved by the Institutional Review Board of Plastic Surgery Hospital, Chinese Academy of Medical Sciences, and the reference number for their judgment is IRB2024-364

doi:10.1046/j.1524-475X.1994.20406.x 9

Exploring the potential of tocopherols: mechanisms of action and perspectives in the prevention and treatment of breast cancer

What we do not know Several questions remain unanswered: Does prolonged amylin receptor agonism produce any adaptive changes in receptor expression or sensitivity that could alter efficacy or safety over years